Clinical news
Every clinical development we have covered, newest first.
Direct answer
2 dated clinical items. Most recent: Semaglutide approved for MASH with moderate to advanced fibrosis (2025-08-15).
All-in monthly cost at 2.4 mg
Stories in this category
Semaglutide approved for MASH with moderate to advanced fibrosis
The first GLP-1 with an FDA liver indication, on accelerated approval, for a narrow population.…
Wegovy gains a cardiovascular risk-reduction indication
The SELECT trial produced an indication that is frequently easier to get covered than weight man…
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.